Boston Scientific Reports Strong Q2 Results and Raises Full-Year Outlook
Boston Scientific (NYSE:BSX) reported second-quarter results that exceeded analyst expectations, with adjusted earnings per share of $0.86 compared to a consensus estimate of $0.83. Revenue reached $5.442 billion, surpassing the expected $5.37 billion and reflecting 7.5% year-over-year growth on both reported and organic bases. The company raised its full-year sales outlook amid strong performance across segments. The Cardiovascular segment saw an 8.3% increase in revenue, while MedSurg grew by 5.9%. Geographically, Asia-Pacific showed the highest regional growth at 11.2%, with Latin America and Canada recording a significant rise of 22.4% on a reported basis. Boston Scientific also completed its $2 billion accelerated share repurchase program during the quarter, buying back around 40 million shares. CEO Mike Mahoney emphasized disciplined execution and long-term growth through innovation.
Tickers: $BSX
Topics: financial_performance medical_devices